Objective: The purpose of this study was to test the hypothesis that the percentage of subspecialists in obstetrics and gynecology who made payments on professional liability claims was less than the percentage of general obstetrician-gynecologists who made payments.
Methods: Professional liability payment data from the Massachusetts Board of Registration in Medicine was used.
Results: During the 10 years preceding August 2005, 38.6% of obstetrician-gynecologists and 32.2% of gynecologists made at least 1 professional liability payment. During the same time period, the percentage of subspecialists who made a payment was significantly less than obstetrician-gynecologists: gynecologic oncologists 10.0% (P = .012), maternal-fetal medicine 3.7% (P = .002), and reproductive endocrinologists 11.9% (P = .016). Using aggregate payment data for the period 1994-2003, the average payment per claim for specialists in maternal-fetal medicine ($1,950,000) and gynecologic oncology ($1,014,006) were above the average payment per claim for obstetrician-gynecologists ($447,983) or gynecologists ($400,338). Reproductive endocrinologists had an average payment per claim of $454,047.
Conclusion: All specialists in the field of obstetrics and gynecology have major professional liability risks. Among subspecialists in obstetrics and gynecology, the favorable trend toward fewer physicians making payments is counterbalanced by greater payments per lost claim.
Level Of Evidence: II-2.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.AOG.0000202400.13898.8b | DOI Listing |
BMC Med Ethics
January 2025
Faculty of Law, University of Montreal, Ch de la Tour, Montreal, QC, H3T 1J7, Canada.
Background: Considering the disruptive potential of AI technology, its current and future impact in healthcare, as well as healthcare professionals' lack of training in how to use it, the paper summarizes how to approach the challenges of AI from an ethical and legal perspective. It concludes with suggestions for improvements to help healthcare professionals better navigate the AI wave.
Methods: We analyzed the literature that specifically discusses ethics and law related to the development and implementation of AI in healthcare as well as relevant normative documents that pertain to both ethical and legal issues.
Rev Col Bras Cir
January 2025
- Hospital de Clínicas de Porto Alegre(HCPA) / Universidade Federal do RIO Grande do Sul (UFRGS), Serviço de Cirurgia Digestiva/Departamento de Cirurgia - Porto Alegre - RS - Brasil.
Robotic surgery is a technological milestone that directly impacts the provision of healthcare services. Procedures that utilize robotics are continuously being developed. In this context, it is important to analyze the distribution of ethical and civil liability among doctors, hospitals, and suppliers of surgical equipment in cases of alleged medical errors or adverse events that may harm patients.
View Article and Find Full Text PDFForensic Sci Med Pathol
January 2025
Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Via Irnerio 49, 40126, Bologna, Italy.
The diagnosis of septic arthritis remains challenging in the clinical setting, often leading to a suspicion for medical liability. Our purpose is to describe an unusual case of a post-mortem diagnosis of P. multocida fatal septic arthritis, in a healthy 67-year-old woman presenting with pain in the right shoulder.
View Article and Find Full Text PDFLancet Digit Health
January 2025
Laboratory for Neuroengineering, Department of Health Science and Technology, Institute for Robotics and Intelligent Systems, ETH Zürich, Zürich, Switzerland; NeuroEngineering Laboratory, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria. Electronic address:
Neuroprosthetics research has entered a stage in which animal models and proof-of-concept studies are translated into clinical applications, often combining implants with artificial intelligence techniques. This new phase raises the question of how clinical trials should be designed to scientifically and ethically address the unique features of neural prostheses. Neural prostheses are complex cyberbiological devices able to acquire and process data; hence, their assessment is not reducible to only third-party safety and efficacy evaluations as in pharmacological research.
View Article and Find Full Text PDFInnov Clin Neurosci
December 2024
Ms. Vanderpool is Director of Risk Management at Professional Risk Management Services (PRMS).
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!